{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10"],"submitter":["Liu L"],"pubmed_abstract":["<h4>Objective</h4>To evaluate the efficacy and safety of omalizumab in the treatment of severe or uncontrolled allergic diseases in children.<h4>Methods</h4>We conducted a systematic search of the PubMed, Embase, CENTRAL, and clinicaltrials.gov databases up to 23rd July 2021, with no language limitations. Randomised controlled trials (RCTs) comparing omalizumab with other treatments or placebo in children with severe or inadequately controlled allergic diseases were considered. The primary outcomes of interest were asthma exacerbation rate, allergic symptom score, desensitisation achievement for food allergy (FA), and incidence of serious adverse events (SAEs). The study selection and data extraction were conducted independently by two researchers. Quality assessments were conducted using "],"journal":["Frontiers in pediatrics"],"pagination":["851177"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8965060"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis."],"pmcid":["PMC8965060"],"pubmed_authors":["Zhai S","Liu L","Zhou P","Zhou W","Wang Z"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis.","description":"<h4>Objective</h4>To evaluate the efficacy and safety of omalizumab in the treatment of severe or uncontrolled allergic diseases in children.<h4>Methods</h4>We conducted a systematic search of the PubMed, Embase, CENTRAL, and clinicaltrials.gov databases up to 23rd July 2021, with no language limitations. Randomised controlled trials (RCTs) comparing omalizumab with other treatments or placebo in children with severe or inadequately controlled allergic diseases were considered. The primary outcomes of interest were asthma exacerbation rate, allergic symptom score, desensitisation achievement for food allergy (FA), and incidence of serious adverse events (SAEs). The study selection and data extraction were conducted independently by two researchers. Quality assessments were conducted using ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-19T00:41:31.445Z","creation":"2025-04-07T11:44:59.461Z"},"accession":"S-EPMC8965060","cross_references":{"pubmed":["35372142"],"doi":["10.3389/fped.2022.851177"]}}